JP2024512386A5 - - Google Patents

Info

Publication number
JP2024512386A5
JP2024512386A5 JP2023555192A JP2023555192A JP2024512386A5 JP 2024512386 A5 JP2024512386 A5 JP 2024512386A5 JP 2023555192 A JP2023555192 A JP 2023555192A JP 2023555192 A JP2023555192 A JP 2023555192A JP 2024512386 A5 JP2024512386 A5 JP 2024512386A5
Authority
JP
Japan
Prior art keywords
polypeptides
bispecific antibody
amino acid
heavy chain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/056416 external-priority patent/WO2022189667A1/en
Publication of JP2024512386A publication Critical patent/JP2024512386A/ja
Publication of JP2024512386A5 publication Critical patent/JP2024512386A5/ja
Pending legal-status Critical Current

Links

JP2023555192A 2021-03-12 2022-03-11 非活性化抗体バリアント Pending JP2024512386A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21162341.8 2021-03-12
EP21162341 2021-03-12
PCT/EP2022/056416 WO2022189667A1 (en) 2021-03-12 2022-03-11 Non-activating antibody variants

Publications (2)

Publication Number Publication Date
JP2024512386A JP2024512386A (ja) 2024-03-19
JP2024512386A5 true JP2024512386A5 (enExample) 2025-03-18

Family

ID=74873608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555192A Pending JP2024512386A (ja) 2021-03-12 2022-03-11 非活性化抗体バリアント

Country Status (11)

Country Link
US (1) US20240150484A1 (enExample)
EP (1) EP4305056A1 (enExample)
JP (1) JP2024512386A (enExample)
KR (1) KR20230156921A (enExample)
CN (1) CN116964085A (enExample)
AU (1) AU2022231895A1 (enExample)
BR (1) BR112023017887A2 (enExample)
CA (1) CA3210971A1 (enExample)
IL (1) IL305636A (enExample)
MX (1) MX2023010567A (enExample)
WO (1) WO2022189667A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2025003280A1 (en) 2023-06-30 2025-01-02 Genmab A/S Antibodies binding to fibroblast activation protein alpha and death receptor 4
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2026090160A2 (en) 2024-10-22 2026-04-30 Gilead Sciences, Inc. Cd4-targeted il-15 molecules and methods of use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US20030082188A1 (en) 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CA2691434C (en) 2007-06-21 2020-07-21 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011047180A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー/エス ヘテロ二量体抗体Fc含有タンパク質およびその産生方法
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
US11180572B2 (en) * 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2016110576A1 (en) * 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
RS61943B1 (sr) * 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
AU2019264217B2 (en) * 2018-05-03 2026-03-05 Genmab B.V. Antibody variant combinations and uses thereof

Similar Documents

Publication Publication Date Title
TWI788286B (zh) 三特異性和/或三價結合蛋白
US9505848B2 (en) Engineered heterodimeric protein domains
US20260116974A1 (en) Novel anti-cd3epsilon antibodies
Merchant et al. An efficient route to human bispecific IgG
JP4324231B2 (ja) へテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US11111305B2 (en) Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
AU2015357053B2 (en) Domain-exchanged antibody
JP2020048564A5 (enExample)
US20240059798A1 (en) Conditionally activated antigen binding polypeptide complexes and methods of use thereof
CN103797033A (zh) 多特异性抗体
JP2021094022A5 (enExample)
US20230365709A1 (en) Trispecific binders
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
CN121712805A (zh) Ch3结构域变体或包含该ch3结构域变体的双特异性抗体
CN119343359A (zh) 多特异性抗体的纯化方法
NZ807450A (en) Antibodies binding to gprc5d
JP2024509695A5 (enExample)
NZ778208A (en) Humanized or chimeric cd3 antibodies
NZ772085B2 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123